To screen ETFs by asset class, performance, yield and more, check out the
View as an RSS Feed
) blockbuster Enbrel drug for treating rheumatoid arthritis, which generated sales of $4.23B last year, is
no more effective
than a combination of three generic treatments, a study shows. While a regimen that includes Enbrel costs $25,000 a year per patient, the "triple therapy" costs just $1,000. The research didn't examine similar drugs from AbbVie (
) or Johnson & Johnson (
), although many doctors consider them to be equivalent to Enbrel. Despite the study, researchers feel that the branded treatments might be too well ensconced to be quickly replaced.
View news story
I do not believe this stub of an article. Enbrel not only took care of my daughters psoriatic arthritis systems it actually helped reverse the damage and after a couple of years she did not need the drug anymore. You would not have gotten this kind of performance from a generic cocktail that is designed to treat symptoms.
Jun 12 06:46 AM
Link to Comment
Xignite quote data
© 2014 Seeking Alpha